Stocks
Halozyme Stock Surges on Growing Investor Confidence in ENHANZE Technology
Halozyme Therapeutics' stock has risen 36.4% in the past month, primarily driven by growing investor confidence in its ENHANZE technology.
The company's novel drug-delivery technology enables the subcutaneous administration of drugs and is used by several large pharma companies.
Halozyme has collaboration agreements with companies like Johnson & Johnson, argenx, and Roche, which use its ENHANZE technology for the development of SC formulations of their approved drugs.